Stereotaxis, Inc. (STXS) Q3 2024 Earnings Call Transcript Summary
Stereotaxis, Inc. (STXS) Q3 2024 Earnings Call Transcript Summary
Recurring revenue increased to $4.8 million this quarter, partly due to the acquisition of APT.The following is a summary of the Stereotaxis, Inc. (STXS) Q3 2024 Earnings Call Transcript:
以下是 Stereotaxis 公司 (STXS) 2024 年第三季度業績會議通話摘要：
Financial Performance:
財務表現:
Stereotaxis reported a revenue of $9.2 million for Q3 2024, an 18% year-over-year increase.
System revenue was $4.4 million, driven by partial revenue recognition from the delivery of three Genesis systems.
Recurring revenue increased to $4.8 million this quarter, partly due to the acquisition of APT.
Gross margin for Q3 stood at 45% of revenue, with a recurring revenue gross margin of 70% and a system gross margin of 16%.
Stereotaxis 報告2024年第三季度營業收入爲$920萬，同比增長18%。
系統營業收入爲$440萬，主要由交付三臺 Genesis 系統部分確認收入所推動。
本季度循環營收增至$480萬，部分歸因於對 APt 的收購。
第三季度毛利率佔營收的45%，循環營收毛利率爲70%，系統毛利率爲16%。
Business Progress:
業務進展：
Successfully closed and integrated the APT acquisition.
Advanced in several regulatory and innovation efforts, notably the near completion of the European CE Mark approval for the MAGiC catheter and progress with robotic cardiovascular devices.
Announced plans to submit regulatory filings for high-density mapping catheter and vascular guidance catheter early in 2025.
成功關閉並整合了 APt 的收購。
在幾個監管和創新努力方面取得了進展，尤其是MAGiC導管接近完成歐洲CE標誌批准，以及機器人心血管設備的進展。
計劃於2025年初提交高密度製圖導管和血管引導導管的監管申請。
Opportunities:
機會：
Expansion into vascular catheters and guide wires indicating opportunities across a broader array of medical specialties.
Increase in European market penetration through the Genesis systems, specifically with the CE mark for Genesis X, vastly expanding the robotic opportunities.
擴展至血管導管和引導線，表明在更廣泛的醫學專業領域有機會。
通過Genesis系統在歐洲市場的滲透增加，特別是Genesis X獲得CE標誌，大大擴展了機器人機會。
Risks:
風險：
Delayed regulatory approvals, particularly noted with pending U.S. FDA and Chinese NMPA evaluations for MAGiC and Genesis systems, which may affect market timings and penetration.
延遲的監管批准，尤其是MAGiC和Genesis系統等待中的美國FDA和中國NMPA評估，可能會影響市場時機和滲透。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。
